SANOFI PASTEUR

🇫🇷France

Country: 🇫🇷France

Ownership: Subsidiary

Established: 1990-01-01

Employees: 10K

Market Cap: -

Website: http://www.sanofipasteur.com

Clinical Trials

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne

Phase 1

Not yet recruiting

Conditions: Acne

Interventions: Biological: Acne mRNA vaccine
Other: Placebo

First Posted Date: 2025-06-10

Last Posted Date: 2025-06-10

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 120

Registration Number: NCT07013747

Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea

Recruiting

Conditions: Hepatitis B
Haemophilus Influenzae Type b Immunisation

Interventions: Biological: DTaP-IPV-Hep B-PRP-T combined vaccine

First Posted Date: 2025-03-25

Last Posted Date: 2025-03-25

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 690

Registration Number: NCT06793826

Locations: 🇰🇷
Investigational Site Number : 002, Cheonan, Korea, Republic of
🇰🇷
Investigational Site Number : 001, Seoul, Korea, Republic of

Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents

Phase 3

Recruiting

Conditions: Pneumococcal Infections

Interventions: Biological: PCV21
Biological: 20vPCV

First Posted Date: 2025-02-20

Last Posted Date: 2025-03-20

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1252

Registration Number: NCT06838000

Locations: 🇺🇸
Site #8400010, Binghamton, New York, United States

Repeated Cross Sectional Surveillance Study To Determine the Respiratory Syncytial Virus (RSV) Immunization Rates in German Infants

Active, not recruiting

Conditions: Respiratory Syncytial Virus Immunization

First Posted Date: 2025-02-13

Last Posted Date: 2025-06-05

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 2400

Registration Number: NCT06824207

Repeated Cross Sectional Surveillance Study To Determine the Influenza Vaccination Rates in German Participants

Active, not recruiting

Conditions: Influenza Immunization

First Posted Date: 2025-01-30

Last Posted Date: 2025-02-21

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 5000

Registration Number: NCT06800885

Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection

Completed

Conditions: Influenza Immunization
Health Volunteers

Interventions: Biological: RIV3

First Posted Date: 2025-01-09

Last Posted Date: 2025-02-13

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 447

Registration Number: NCT06765187

Locations: 🇺🇸
Investigational site, Swiftwater, Pennsylvania, United States

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Phase 1

Active, not recruiting

Conditions: Influenza
Healthy Volunteers

Interventions: Biological: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
Biological: TIV mRNA-HA Vaccine 2
Biological: Quadrivalent Influenza Standard Dose Vaccine
Biological: Quadrivalent Influenza Vaccine High Dose
Biological: TIV mRNA-neuraminidase (NA)

First Posted Date: 2024-12-20

Last Posted Date: 2025-05-30

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1162

Registration Number: NCT06744205

Locations: 🇦🇺
Investigational Site Number : 0360003, Bayswater, Victoria, Australia
🇦🇺
Investigational Site Number : 0360002, Melbourne, Victoria, Australia
🇺🇸
Accel Research Sites Network - Birmingham- Site Number : 8400008, Birmingham, Alabama, United States

and more 21 locations

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Phase 3

Recruiting

Conditions: Pneumococcal Immunization

Interventions: Biological: PCV21 vaccine
Biological: Prevnar 20 vaccine
Biological: M-M-R II vaccine
Biological: RotaTeq
Biological: Vaxelis vaccine
Biological: Varivax
Biological: Hexaxim Vaccine

First Posted Date: 2024-12-16

Last Posted Date: 2025-05-20

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 1630

Registration Number: NCT06736041

Locations: 🇺🇸
Eclipse Clinical Research- Site Number : 8400029, Tucson, Arizona, United States
🇺🇸
Northwest Arkansas Pediatrics- Site Number : 8400030, Fayetteville, Arkansas, United States
🇺🇸
Century Research Institute- Site Number : 8400065, Huntington Park, California, United States

and more 67 locations

Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older

Phase 1

Active, not recruiting

Conditions: Influenza Immunization

Interventions: Biological: Pandemic flu H5 mRNA vaccine
Other: Placebo

First Posted Date: 2024-12-10

Last Posted Date: 2025-02-20

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 276

Registration Number: NCT06727058

Locations: 🇺🇸
Velocity Clinical Research - San Diego- Site Number : 8400013, La Mesa, California, United States
🇺🇸
Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400002, DeLand, Florida, United States
🇺🇸
ARSN-Lakeland CRU- Site Number : 8400006, Lakeland, Florida, United States

and more 11 locations

A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

Phase 3

Active, not recruiting

Conditions: RSV Immunisation

Interventions: Biological: Standard Dose (SD) RSVt vaccine
Biological: Placebo
Biological: High Dose (HD) RSVt vaccine
Biological: Low Dose (LD) RSVt vaccine

First Posted Date: 2024-11-26

Last Posted Date: 2025-01-14

Lead Sponsor: Sanofi Pasteur, a Sanofi Company

Target Recruit Count: 947

Registration Number: NCT06705140

Locations: 🇩🇴
Investigational Site Number : 2140002, Santo Domingo, Dominican Republic
🇭🇳
Investigational Site Number : 3400002, San Pedro Sula, Honduras
🇭🇳
Investigational Site Number : 3400001, Tegucigalpa, Honduras

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy